-
-
Using HIV drugs like Truvada could double the risks of a common form of glaucoma, which can cause vision problems and blindness.
-
The U.S. and Gilead have reached a settlement agreement involving patent rights to two HIV drugs, Truvada and Descovy, which are used as pre-exposure prophylaxis treatments to prevent the spread of HIV.
-
Drug maker says twice-yearly injection could be more effective at preventing HIV infections than Truvada, which is a daily PrEP pill that has been linked to reports of kidney injuries, bone fractures and other concerns.
-
The U.S. government has asked a federal appeals court to overturn a 2023 jury verdict, which rejected claims that Gilead illegally profited from its patent on certain HIV drugs that the CDC helped the manufacturer develop.
-
Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.
-
A TDF lawsuit filed by 26 plaintiffs claims Gilead purposefully exposed them to increased kidney disease and bone fracture risks from its older HIV drugs to increase profits.
-
A California appeals court has cleared the way for 24,000 lawsuits over Truvada and other TDF-based Gilead HIV drugs to proceed on claims of negligence.
-
Kaiser Permanente researchers warn that the side effects of Descovy could result in an increased risk of hypertension and the need for cholesterol control.
-
A California appeals court is weighing whether Gilead had a responsibility to develop safer HIV drugs to replace older ones with a higher risk of kidney damage and bone fractures.